PRESS RELEASE published on 09/29/2025 at 23:00, 3 months 29 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 3 months 29 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 5 months ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 5 months ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 6 months 12 days ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
PRESS RELEASE published on 07/17/2025 at 15:00, 6 months 12 days ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 6 months 12 days ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
BRIEF published on 07/03/2025 at 21:24, 6 months 25 days ago GenSight Biologics completes private placement of nearly €4 million Private Placement Common Shares Euronext Funding GenSight Biologics
PRESS RELEASE published on 07/03/2025 at 21:19, 6 months 25 days ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics closes EUR 3.9M private placement with issuance of ordinary shares, pre-funded warrants, investor warrants. Funds to repay convertible bonds. Maxim Group, LLC acted as placement agent Private Placement Ordinary Shares GenSight Biologics Maxim Group EUR 3.9M
BRIEF published on 07/01/2025 at 08:59, 6 months 28 days ago GenSight Biologics raises nearly €4 million in private placement Private Placement Investment GenSight Biologics Euronext Shares LUMEVOQ ®
Published on 01/29/2026 at 17:00, 1 hour 7 minutes ago Sparta Reports on Delay in Filing Annual Financial Statements
Published on 01/29/2026 at 14:30, 3 hours 37 minutes ago Innodata Selected by Palantir to Accelerate Advanced Initiatives in AI-Powered Rodeo Modernization
Published on 01/29/2026 at 14:00, 4 hours 7 minutes ago Horizon Aircraft Partners with RAMPF to Manufacture the Fuselage for its Aircraft
Published on 01/29/2026 at 14:00, 4 hours 7 minutes ago GameSquare's Stream Hatchet Publishes Annual 2025 Live Streaming Trends Report
Published on 01/29/2026 at 14:00, 4 hours 7 minutes ago Char Tech Commences Commissioning at Thorold Renewable Energy Facility
Published on 01/29/2026 at 17:52, 14 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/29/2026 at 17:45, 22 minutes ago Burkhalter Group acquires Elektro Gasser AG in Lalden (VS)
Published on 01/29/2026 at 17:00, 1 hour 7 minutes ago VAZIVA SA: 2025 revenue: €67.6 million (+67.2%) - Confirmation of strong growth momentum
Published on 01/29/2026 at 15:56, 2 hours 11 minutes ago EQS-Adhoc: ASTA ENERGY SOLUTIONS AG SETS FINAL OFFER PRICE FOR IPO AT EUR 29.50
Published on 01/29/2026 at 18:00, 7 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 22 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 22 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 10:07, 7 hours 59 minutes ago Deezer confirms demonetization of up to 85% of AI-music streams due to fraud and moves to sell AI-detection tech
